Merdad Parsey
Chief Tech/Sci/R&D Officer bei GILEAD SCIENCES, INC.
Vermögen: 7 Mio $ am 31.03.2024
Profil
Dr. Merdad V. Parsey ist ein unabhängiger Direktor bei Arcus Biosciences, Inc. und ein Chief Medical Officer bei Gilead Sciences, Inc. Er ist Mitglied des Board of Directors bei Arcus Biosciences, Inc. und Sagimet Biosciences, Inc. Dr. Parsey war zuvor als Senior Medical Director bei Regeneron Pharmaceuticals, Inc. angestellt, als Senior Director-Medical Group bei Genentech, Inc. als Associate Medical Director bei Merck & Co, Inc. als Director-Critical Care Medicine bei der New York University School of Medicine, als Mitglied bei der Roche Group und als Senior Medical Director bei Sunovion Pharmaceuticals, Inc. Er erhielt seinen Doktortitel von der University of Maryland.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
GILEAD SCIENCES, INC.
0,01% | 01.04.2024 | 96 304 ( 0,01% ) | 7 Mio $ | 31.03.2024 |
18.07.2023 | 12 794 ( 0,06% ) | 69 343 $ | 31.03.2024 |
Aktive Positionen von Merdad Parsey
Unternehmen | Position | Beginn |
---|---|---|
SAGIMET BIOSCIENCES INC. | Director/Board Member | 30.09.2010 |
GILEAD SCIENCES, INC. | Chief Tech/Sci/R&D Officer | 01.11.2019 |
ARCUS BIOSCIENCES, INC. | Director/Board Member | 13.07.2020 |
Transcelerate Biopharma, Inc.
Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Director/Board Member | - |
Ehemalige bekannte Positionen von Merdad Parsey
Unternehmen | Position | Ende |
---|---|---|
REGENERON PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01.01.2004 |
New York University School of Medicine | Corporate Officer/Principal | - |
MERCK & CO., INC. | Corporate Officer/Principal | - |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Chief Tech/Sci/R&D Officer | - |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Corporate Officer/Principal | - |
Ausbildung von Merdad Parsey
University of Maryland | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 5 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
MERCK & CO., INC. | Health Technology |
REGENERON PHARMACEUTICALS, INC. | Health Technology |
SAGIMET BIOSCIENCES INC. | Health Technology |
ARCUS BIOSCIENCES, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Finance |
Transcelerate Biopharma, Inc.
Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Health Technology |